Mounjaro vs Zepbound: What Changed and What Didn't

When Eli Lilly launched Zepbound in late 2023, a great many people assumed a new drug had arrived — something distinct from the Mounjaro that had been making headlines for diabetes and, increasingly, for weight loss. It had not. Zepbound and Mounjaro are the same molecule, tirzepatide, manufactured by the same company, supplied at the same doses, and acting through the same mechanism in the body. Pour the contents of a Mounjaro pen and a Zepbound pen into two unlabelled vials and no laboratory on earth could tell them apart.

What changed was not the chemistry. What changed was the writing on the box — specifically, the FDA-approved indication. Mounjaro is tirzepatide approved for type 2 diabetes. Zepbound is tirzepatide approved for chronic weight management. That distinction sounds like a regulatory footnote, and pharmacologically it is. But it is the single most consequential fact about these two products, because the label — not the molecule — is what determines whether your insurance pays, which savings programme you qualify for, and which prescription your clinician is in a position to write. This article unpacks what is genuinely identical between the two, what the label actually governs, and how to think about which one applies to you.

The Same Molecule, Two Approvals

Tirzepatide reached the United States market first as Mounjaro, approved by the FDA in May 2022 for improving blood-sugar control in adults with type 2 diabetes. As with several drugs in this class, substantial weight loss showed up in the diabetes trials as a powerful secondary effect — large enough that clinicians and patients began using Mounjaro off-label for weight management well before any weight-specific approval existed.

Eli Lilly then ran the dedicated obesity trial programme, SURMOUNT, and on the strength of those results the FDA approved Zepbound in November 2023 specifically for chronic weight management — in adults with obesity (a BMI of 30 or higher) or overweight (a BMI of 27 or higher) accompanied by at least one weight-related condition such as hypertension, dyslipidaemia, or obstructive sleep apnoea. In late 2024 Zepbound additionally gained an FDA indication for moderate-to-severe obstructive sleep apnoea in adults with obesity, a use Mounjaro does not carry. The active ingredient remained tirzepatide throughout; Zepbound is simply the weight-management identity of the same compound.

The available doses are identical across both brands: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, delivered as a once-weekly subcutaneous injection. The 2.5 mg dose is a starting and titration step rather than a therapeutic target in either product. There is no Zepbound dose that does not also exist as a Mounjaro dose, and the titration logic is the same in both. If you want the underlying pharmacology in depth, see how tirzepatide works; this piece concentrates on what the two-brand split means in practice.

Mounjaro and Zepbound at a Glance

	Mounjaro	Zepbound
Active drug	Tirzepatide	Tirzepatide
FDA-approved use	Type 2 diabetes (blood-sugar control)	Chronic weight management; moderate-to-severe obstructive sleep apnoea with obesity
Available doses	2.5, 5, 7.5, 10, 12.5, 15 mg	2.5, 5, 7.5, 10, 12.5, 15 mg
Dosing schedule	Once weekly; start at 2.5 mg, increase by 2.5 mg no sooner than every 4 weeks as tolerated	Once weekly; identical titration to Mounjaro
Typical coverage	Commercial and Medicare Part D plans commonly cover it for diabetes; Medicare covers it for the diabetes indication	Coverage for weight management is inconsistent across commercial plans; Medicare Part D historically excludes weight-loss drugs, though the OSA indication has begun to open limited pathways
Who it's for	Adults with type 2 diabetes (weight loss is a secondary benefit)	Adults with obesity, or overweight plus a weight-related condition, without diabetes — and adults with obesity and OSA

The table makes the central point visually: read across almost any row and the two columns are the same. It is only the indication row, and the coverage row that follows from it, where they diverge. Everything downstream of access — the molecule, the dose, the mechanism, the side-effect profile, the expected weight loss — is shared.

What Tirzepatide Actually Does

To understand why the same molecule earns two labels, it helps to understand what that molecule does, because tirzepatide acts on both blood sugar and body weight through one unified mechanism. Tirzepatide is a dual agonist: a single engineered peptide that activates two gut-hormone receptors at once — the GLP-1 receptor and the GIP receptor. Most of this drug class engages GLP-1 alone. Tirzepatide engages both, which is the basis of much of the clinical interest in it. The distinction between the two incretin hormones, and why combining them appears to matter, is laid out in the difference between GLP-1 and GIP.

The GLP-1 arm is the better understood of the two. GLP-1 is a hormone released by the gut after eating, and Drucker's 2018 synthesis describes its core actions: it stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows the rate at which the stomach empties, and acts on the brain to enhance satiety. Because the insulin effect is glucose-dependent — switching off when blood sugar is normal or low — GLP-1-based drugs used on their own carry a relatively low risk of hypoglycaemia, which is part of why they became diabetes drugs first. The appetite side runs through the brain as well as the gut: van Bloemendaal's 2014 imaging work showed that GLP-1 receptor activation specifically dampens the reward system's response to food cues, the neurobiological basis of the quieted "food noise" many patients describe. The same reward circuitry, as Volkow's work documents, is the one that palatable food engages most intensely in people with obesity.

The GIP arm is more ambiguous, and honesty requires saying so. GIP is the other major incretin, and its role in body weight has genuinely puzzled the field — both activating and blocking the GIP receptor have shown weight-loss potential in different experimental settings. The leading hypothesis is that sustained GIP receptor activation may eventually produce an effect resembling functional antagonism, but this remains an open research question rather than settled science. What is not ambiguous is the clinical result: engaging both receptors outperforms engaging GLP-1 alone, and that is the same whether the resulting weight loss is being marketed as a Mounjaro benefit or a Zepbound one.

This dual identity — a drug that lowers blood sugar and reduces body weight through the same hormonal action — is precisely why one molecule can carry two labels without contradiction. The signals that manage how a meal is metabolised and the signals that manage whether to keep eating are biologically linked, and tirzepatide exploits both at once. Mounjaro and Zepbound are not two uses of two drugs; they are two regulatory framings of one drug doing one thing.

What the Trials Show

The weight-management approval for Zepbound rests on the SURMOUNT trial programme, and SURMOUNT-1 in particular is the study that defined what tirzepatide can do for weight. Led by Ania Jastreboff at Yale and published in the New England Journal of Medicine in 2022, SURMOUNT-1 randomised 2,539 adults with obesity, or overweight with a weight-related complication, and without diabetes, to one of three tirzepatide doses — 5 mg, 10 mg, or 15 mg — or to placebo, over 72 weeks. Mean weight loss was 15.0% on the 5 mg dose, 19.5% on 10 mg, and 20.9% on the highest 15 mg dose, against 3.1% on placebo. On the top dose, the average participant lost roughly a fifth of their starting body weight, and more than half of those on 15 mg lost more than 20% — figures that overlap, at the high end, with what bariatric surgery has historically achieved. The fuller breakdown sits in the Zepbound clinical trial results.

It is worth being clear that those figures come from the obesity programme that supports the Zepbound label, but the molecule generating them is the identical molecule sold as Mounjaro. A person taking 15 mg of Mounjaro for diabetes is taking the same drug, at the same dose, that produced the SURMOUNT-1 weight loss. The trials are separated by indication and trial population, not by chemistry. The diabetes programme (SURPASS) and the obesity programme (SURMOUNT) studied the same compound in different groups of people to satisfy different regulatory requirements.

Two caveats from the trial evidence deserve emphasis, and they apply to either brand. First, the weight loss was achieved while taking the medication; the trials describe what the drug does during treatment, not after it. Second, averages conceal wide individual variation — some participants lost a great deal, others relatively little, and the trials do not identify in advance who will land where. These are population results, not personal forecasts.

How It Compares to Semaglutide

The most common point of confusion after "are Mounjaro and Zepbound the same" is "how does this compare to Ozempic and Wegovy." Those are semaglutide, a GLP-1 receptor agonist that engages a single receptor rather than two. In the comparable obesity trial for semaglutide — STEP 1, led by John Wilding and published in 2021 — once-weekly semaglutide titrated to 2.4 mg produced a mean weight loss of about 14.9% over 68 weeks, against roughly 2.4% on placebo. Set beside SURMOUNT-1's 20.9% on high-dose tirzepatide, the dual agonist produced the larger average loss, which is the basis for much of the clinical interest in it. A head-to-head treatment view is laid out in the tirzepatide versus semaglutide comparison.

The structural parallel between the two drug families is worth noticing, because it clarifies the whole naming landscape. Semaglutide is sold as Ozempic for diabetes and Wegovy for weight management — one molecule, two labels — exactly as tirzepatide is sold as Mounjaro for diabetes and Zepbound for weight management. The Mounjaro/Zepbound split is not an idiosyncrasy of tirzepatide; it is the standard regulatory pattern for this entire class, in which the diabetes indication and the obesity indication are pursued as separate approvals even when the underlying drug is one and the same.

Side Effects: The Same in Both

Because the molecule and doses are identical, the side-effect profile of Mounjaro and Zepbound is identical too. The dominant effects are gastrointestinal: nausea, diarrhoea, constipation, vomiting, and a general sense of early fullness. In SURMOUNT-1 these were the most common adverse events, generally mild to moderate, and they led only a small minority to discontinue. They follow directly from the slowed gastric emptying that is part of how the drug produces satiety in the first place — the nausea is, in effect, the appetite mechanism overshooting, and for most people it settles substantially over weeks as the body adapts.

This is why titration is built into the dosing of both brands: treatment starts at 2.5 mg and steps up gradually, giving the gastrointestinal system time to adapt at each level before the dose rises. Rushing or skipping titration steps is one of the most common reasons people experience side effects severe enough to stop. Beyond titration, the same practical strategies apply regardless of which brand is on the box — smaller and slower meals, less high-fat food, adequate hydration. One consequence of sharply reduced intake also deserves attention in both cases: the risk of inadequate protein, which can accelerate loss of lean muscle alongside fat, and which is why clinicians using these drugs emphasise deliberate protein intake and resistance training.

The rarer but more serious considerations are likewise shared: pancreatitis, gallbladder disease (weight loss of any kind raises gallstone risk), and a contraindication in people with a personal or family history of medullary thyroid carcinoma, derived from rodent studies of the drug class. None of these differ between Mounjaro and Zepbound, because none of them are properties of the label. They are properties of the molecule.

Dosing and Titration

Both products are once-weekly subcutaneous injections, available as single-dose pens, taken on the same day each week with or without food, and rotated among injection sites (abdomen, thigh, or upper arm). The standard schedule starts at 2.5 mg weekly for four weeks — a dose intended purely to let the gut acclimatise, not to drive results — then increases to 5 mg, with further 2.5 mg increases permitted no sooner than every four weeks as tolerated, up to a maximum of 15 mg. The maintenance dose is whichever step delivers the desired effect at acceptable tolerability; not everyone needs to reach 15 mg, and some do well at 5 or 10 mg.

Because the titration ladder is identical, switching between the brands is pharmacologically seamless. A patient moving from Mounjaro 10 mg to Zepbound 10 mg is continuing the same dose of the same drug and does not restart titration. The reasons to switch are almost never clinical; they are about which label the patient's coverage will pay for, a point this article keeps returning to because it is the heart of the matter.

Why the Label Controls Everything

Here is the mechanism that makes a regulatory footnote into a financial reality. Insurance formularies are built around FDA-approved indications, not around active ingredients. A plan does not ask "is this tirzepatide"; it asks "is this drug approved, and covered under our plan, for the condition being treated." That single design choice produces consequences that feel arbitrary but are entirely systematic:

• A plan that covers Mounjaro for diabetes does not automatically cover Zepbound for weight management — even though the molecule is identical — because the two are filed under different indications.
• A plan that covers Zepbound for weight management may apply different cost-sharing, prior-authorisation rules, or step-therapy requirements than it applies to Mounjaro.
• Medicare Part D has historically been prohibited from covering drugs used for weight loss, which is why Zepbound's Medicare coverage has been limited despite containing the same active ingredient as a Medicare-covered diabetes drug. The 2024 obstructive-sleep-apnoea indication has begun to open narrow, condition-specific coverage pathways, but the general weight-management exclusion has remained the dominant reality.

The result is a situation many patients find genuinely maddening: two boxes containing the same liquid, one of which their insurer pays for and one of which it does not, with the deciding factor being which of two diagnoses appears on the prescription. None of this reflects a pharmacological difference. It reflects how the payment system is wired. The biology blurs the line between treating diabetes and treating obesity — it is one drug acting on one hormonal system — while the regulatory and insurance architecture draws that line sharply.

Cost and Savings Cards

List prices for both Mounjaro and Zepbound run to roughly a thousand dollars or more per month before insurance, though the amount any individual pays varies enormously with coverage. Eli Lilly operates separate savings-card programmes for the two brands, with their own eligibility rules and copay structures, and the terms have been revised repeatedly. Commercially insured patients whose plans cover the drug have at times been able to reduce monthly out-of-pocket costs substantially through these cards; patients without coverage have generally faced much higher costs, and the assistance available to them has been narrower.

The practical implications follow directly from the separate-programme structure. Enrolment in the Mounjaro programme does not carry over to Zepbound; a patient switching brands must enrol again under the new programme, and eligibility — particularly the common exclusion of government-insured patients such as those on Medicare or Medicaid — may differ between the two. Eli Lilly has also offered self-pay vials of single-dose tirzepatide at lower-tier doses through a direct pharmacy channel, priced below the branded pen list price, as an additional cash-pay route. Because all of these figures and terms change frequently, they should be verified directly with the manufacturer's official programme pages or a pharmacist rather than treated as fixed. These are descriptive approximations, not quotes.

How to Choose

For nearly everyone, the choice between Mounjaro and Zepbound is not a pharmacological decision — both deliver identical tirzepatide — but an access decision, made with a prescriber and an eye on your specific coverage. The rough logic:

• You have type 2 diabetes. Mounjaro is the on-label option. Coverage is more likely, and your prescriber can document the diabetes indication straightforwardly. The weight loss comes along as a secondary benefit.
• You have obesity, or overweight with a weight-related condition, but not diabetes. Zepbound is the correctly indicated product. Whether your plan pays depends heavily on its weight-management policy, which is where prior authorisation and step therapy tend to enter.
• You have both. Your prescriber has some flexibility in how the prescription is framed, and the practical question becomes which label your insurer covers more readily. This is a conversation to have explicitly with the clinician and, often, the insurer.
• You have obesity with obstructive sleep apnoea. Zepbound's OSA indication may matter for coverage, and is worth raising specifically.

What should not drive the choice is any belief that one brand works better than the other for the same person at the same dose. It does not. The deciding variables are diagnosis, coverage, prior-authorisation burden, and cost — not efficacy. If both are equally covered and equally affordable for you, they are interchangeable. The broader question of using tirzepatide for weight loss in the absence of diabetes is covered in Mounjaro for weight loss without diabetes.

What Stopping Looks Like — for Either Brand

One more thing is identical between the two products, and it is the question patients most often underestimate: what happens when treatment ends. Because Mounjaro and Zepbound are the same drug, the answer is the same for both, and it is the same answer that applies across this class. For most people, on current evidence, much of the lost weight returns after stopping.

The clearest evidence comes from the semaglutide trials, but the underlying biology is drug-agnostic. The STEP 4 trial, led by Domenica Rubino and published in 2021, gave participants semaglutide for twenty weeks and then randomised them to continue or switch to placebo; the placebo group regained roughly two-thirds of their lost weight over the following year while the continuation group kept losing. Wilding's STEP 1 trial extension found the same pattern after the drug was withdrawn. The reason is not a defect of any particular medication. After weight loss the body mounts a coordinated defence: Sumithran's 2011 work showed appetite-regulating hormones remaining dysregulated toward regain a full year after a diet ended, and Leibel's classic 1995 study showed resting energy expenditure falling by more than body-size change alone predicts. Müller's 2018 synthesis describes a system that resists downward shifts in weight through coordinated changes in hunger, satiety, and expenditure, and Anderson's 2001 meta-analysis found that people maintained only about 23% of their initial loss at five years. Fothergill's six-year follow-up of The Biggest Loser contestants showed the metabolic adaptation persisting long after the weight-loss effort ended.

Seen against that background, tirzepatide — under either name — counters the body's defence of its prior weight for as long as it is present, and when withdrawn, the defence reasserts itself. This is why obesity medicine increasingly frames these drugs as ongoing management of a chronic condition rather than a time-limited course, closer in logic to blood-pressure medication than to a round of antibiotics. The framing applies equally to Mounjaro and Zepbound, because it is a property of the molecule and the biology, not of the label. The wider scientific context for all of this sits in the complete guide to GLP-1 medications and weight science, and the related articles are gathered in the GLP-1 science hub.